Ono Pharmaceutical (OPHLF) 107.0795 $OPHLF
Receptos Q1 Loss Wider-Than-Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 06, 1:21PM CDT
Receptos, Inc. (RCPT) reported a loss of $1.29 per share in the first quarter of 2015, much wider than the Zacks Consensus Estimate of a loss of $1.19 and the year-ago loss of $1.01 per share.
AEZS: 0.42 (-0.01), ILMN: 200.76 (+1.69), RCPT: 163.64 (+3.24)
Gastroesophageal (GE) Junction Carcinomas Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 07, 6:30AM CDT
The report "Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas. The gastroesophageal junction lies at the top of the stomach in the upper abdomen. Conditions that afflict the gastroesophageal junction include hiatal hernia. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/gastroesopha...eport.html .
MACK: 13.07 (+0.41), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22), AZN: 68.74 (-0.55), BMY: 68.00 (+0.36), EXEL: 3.34 (-0.03)
Esophageal Cancer Therapeutics Pipeline Review 2015 - 40 Companies & 57 Drug Profiles
M2 - Wed Mar 11, 7:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2mqnm8/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Advaxis, Inc. - Amgen Inc. - ArQule, Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellectar Biosciences, Inc. - Cerulean Pharma, Inc. - Daiichi Sankyo Company, Limited - Genmab A/S - GlaxoSmithKline plc - Glycotope GmbH - Hutchison MediPharma Limited - ImmunoFrontier, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Karyopharm Therapeutics, Inc. - Mebiopharm Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Omeros Corporation - Omnitura Therapeutics Inc. - Oncolys BioPharma Inc. - Ono Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2m...eal_cancer
CLRB: 2.80 (+0.06), IMMU: 4.22 (+0.10), ADXS: 20.90 (+0.82), CERU: 6.37 (+0.22), IMGN: 8.67 (+0.08), ARQL: 1.85 (-0.02), AMGN: 163.44 (+1.08), GSK: 44.66 (-0.11), BMY: 68.00 (+0.36), OMER: 20.99 (+0.11), MACK: 13.07 (+0.41), BLCM: 22.18 (-0.84), AZN: 68.74 (-0.55), AVEO: 1.24 (+0.05), NVS: 104.06 (+0.31), KPTI: 27.02 (+2.21), CELGZ: 2.60 (unch)
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
OCAT: 6.42 (+0.21), ITEK: 5.85 (+0.05), NBS: 2.37 (-0.01), FOMX: 11.36 (-0.05), AERI: 11.22 (-0.04), OCUL: 26.43 (+0.16), AGN: 240.22 (+2.88), CANF: 2.43 (+0.10), ACAD: 40.31 (+1.14), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22), TEVA: 60.19 (-0.04), OHRP: 2.77 (+0.04), CBMG: 29.54 (+2.04)
Gilead/Ono Pharmaceutical Ink Deal for Blood Cancer Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 3:12PM CST
Gilead Sciences, Inc. and Ono Pharmaceutical Co., Ltd. announced that they have entered into an agreement for ONO-4059.
VRX: 225.43 (+0.80), GILD: 111.00 (+1.70), SCMP: 16.04 (+0.10)
Gilead teams up with Ono to develop cancer med
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 10:19AM CST
GILD: 111.00 (+1.70)
ONO and Gilead Announce Exclusive License Agreement to Develop BTK Inhibitor, ONO-4059, for the Treatment of B-cell Malignancies and Other Diseases
Business Wire - Fri Dec 19, 12:00AM CST
ONO PHARMACEUTICAL CO., LTD. ("ONO"
and Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the companies have entered into an exclusive license agreement for the development and commercialization of ONO-4059, ONO's oral Bruton's tyrosine kinase (BTK) inhibitor for the treatment of B-cell malignancies and other diseases. Under the terms of the agreement, Gilead will pay ONO an upfront payment plus additional payments based upon achievement of certain development, regulatory and commercial milestones. The companies will collaborate jointly on global development of ONO-4059. Gilead will have exclusive rights to develop and commercialize ONO-4059 in all countries of the world outside of Japan, South Korea, Taiwan, China and the Association of Southeast Asian Nations (ASEAN) countries, where ONO retains development and commercialization rights.
GILD: 111.00 (+1.70)
Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.71 (unch), PFE: 33.98 (-0.01), INCY: 107.65 (+0.79), CLDX: 26.26 (+0.45), AMGN: 163.44 (+1.08), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), MNTA: 20.22 (-0.07), PVCT: 0.85 (-0.02), VICL: 0.92 (-0.01), AZN: 68.74 (-0.55), DCTH: 0.86 (+0.03), NVS: 104.06 (+0.31), CELGZ: 2.60 (unch)
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/kspvsg/recurrent_head) has announced the addition of the "Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Genentech, Inc. - MedImmune, LLC - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Merck KGaA - Oncolytics Biotech Inc. - Panacea Biotec Limited - PCI Biotech AS - Glycotope GmbH - VentiRx Pharmaceuticals, Inc. - Immunovative Therapies, Ltd. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/ks...rrent_head
ONCY: 0.71 (unch), PFE: 33.98 (-0.01), AMGN: 163.44 (+1.08), NVS: 104.06 (+0.31)
Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors
Business Wire - Wed Dec 10, 5:00AM CST
Ono Pharmaceutical Co.,Ltd. (Tokyo: 4528), Bristol-Myers Squibb Company (NYSE:BMY) and Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151,"Kyowa Hakko Kirin" announced today the companies have entered into a clinical trial collaboration agreement to conduct a Phase 1 combination study with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, and mogamulizumab, an anti-CCR4 antibody. The study, which will be conducted in Japan, will focus on evaluating the safety, tolerability and anti-tumor activity of combining Opdivo and mogamulizumab as a potential treatment option for patients with advanced or metastatic solid tumors.
BMY: 68.00 (+0.36)
Global Irritable Bowel Syndrome Therapeutics Pipeline Review 2014 - 28 Companies & 33 DRug Profiles
M2 - Fri Nov 07, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/scknzx/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Astellas Pharma Inc. - Ono Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - AlbireoPharma - Lexicon Pharmaceuticals, Inc. - Yuhan Corporation - Alba Therapeutics Corporation - Ironwood Pharmaceuticals, Inc. - Rottapharm SpA - Tioga Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Drais Pharmaceuticals, Inc. - Synergy Pharmaceuticals, Inc. - Protagonist Therapeutics Inc. - Alfa Wassermann S.p.A - RaQualia Pharma Inc. - Furiex Pharmaceuticals, Inc. - Hanmi Pharmaceuticals, Co. Ltd. - X-BODY BioSciences, Inc. - ImmusanT, Inc. - AltheRx Pharmaceuticals, Inc. - GIcare Pharma Inc - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/sc...able_bowel
SGYP: 3.90 (+0.38), SYN: 1.94 (+0.07), IRWD: 14.30 (+0.02), LXRX: 1.01 (unch), AZN: 68.74 (-0.55), TEVA: 60.19 (-0.04)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 33.98 (-0.01), INCY: 107.65 (+0.79), ONTX: 2.81 (+0.09), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), STML: 13.42 (-0.01), SNTA: 2.34 (+0.01), KBIO: 0.50 (unch), BPTH: 1.30 (+0.06), CELGZ: 2.60 (unch), NVS: 104.06 (+0.31)
Global B-Cell Non-Hodgkin Lymphoma Therapeutics Pipeline Review H2 2014 - 43 Drug Profiles from 28 Leading Pharma Companies
M2 - Thu Oct 23, 10:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72dlvw/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - Sanofi - Seattle Genetics, Inc. - Genentech, Inc. - MedImmune, LLC - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Biocon Limited - Ono Pharmaceutical Co., Ltd. - Sandoz Inc. - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics, Inc. - Portola Pharmaceuticals, Inc. - Pharmacyclics, Inc. - Takara Bio Inc. - Simcere Pharmaceutical Group - Spectrum Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - LFB S.A. - Eagle Pharmaceuticals Inc. - Areta International s.r.l. - Molecular Templates Inc. - Aprogen, Inc. - BioMedics Japan Inc. For more information visit http://www.researchandmarkets.com/research/72dlvw/bcell
IMMU: 4.22 (+0.10), PTLA: 37.66 (+0.45), PCYC: 258.23 (+2.81), INCY: 107.65 (+0.79), AMGN: 163.44 (+1.08), SPPI: 6.56 (-0.12), BMY: 68.00 (+0.36), EGRX: 61.94 (+1.02), SGEN: 40.50 (+0.56), MRK: 60.01 (-0.22), CELGZ: 2.60 (unch)
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - 22 Drug Profiles from 11 Companies
M2 - Fri Sep 12, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c97xhn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Santen Pharmaceutical Co., Ltd. - Oxford BioMedica plc - Sylentis S.A. - Ono Pharmaceutical Co., Ltd. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Amakem NV Drug Profiles - tafluprost - (tafluprost timolol maleate) - latanoprostene bunod - latanoprost - OPC-1085EL - trabodenoson - SYL-040012 - RO-5093151 - latanoprost - AR-13324 - AMA-0076 - ONO-9054 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - latanoprost SR - Glaucoma-GT - ATS-8535 - Small Molecule for Glaucoma For more information visit http://www.researchandmarkets.com/research/c97xhn/openangle
AERI: 11.22 (-0.04)
Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer
MGNX: 32.83 (+1.99), ADXS: 20.90 (+0.82), IMMU: 4.22 (+0.10), CERU: 6.37 (+0.22), AMGN: 163.44 (+1.08), BMY: 68.00 (+0.36), CTIC: 1.78 (-0.02), GSK: 44.66 (-0.11), OMER: 20.99 (+0.11), MACK: 13.07 (+0.41), SNTA: 2.34 (+0.01), GILD: 111.00 (+1.70), KITE: 46.39 (-3.63), NVS: 104.06 (+0.31)
Merck KGaA-Ono Pharma Deal Ends - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 5:15PM CDT
Merck KGaA (MKGAF) has decided to terminate its license agreement with Ono Pharma related to the development of Ono Pharma's multiple sclerosis candidate, ceralifimod (ONO-4641).
GILD: 111.00 (+1.70), ARIA: 9.12 (+0.23)
Ocular Hypertension - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bzfhkc/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Allergan, Inc. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. - Kowa Company, Ltd. - Ono Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Can-Fite BioPharma Ltd. - Lexicon Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - D. Western Therapeutics Institute, Inc. - Icon Bioscience, Inc. - Otsuka Holdings Co., Ltd. - Ocular Therapeutix, Inc. - Amakem NV - High Point Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/bzfhkc/ocular
CANF: 2.43 (+0.10), AGN: 240.22 (+2.88), LXRX: 1.01 (unch), AERI: 11.22 (-0.04)
Receptos Q1 Loss Wider-Than-Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 06, 1:21PM CDT
Receptos, Inc. (RCPT) reported a loss of $1.29 per share in the first quarter of 2015, much wider than the Zacks Consensus Estimate of a loss of $1.19 and the year-ago loss of $1.01 per share.
AEZS: 0.42 (-0.01), ILMN: 200.76 (+1.69), RCPT: 163.64 (+3.24)
Gastroesophageal (GE) Junction Carcinomas Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 07, 6:30AM CDT
The report "Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas. The gastroesophageal junction lies at the top of the stomach in the upper abdomen. Conditions that afflict the gastroesophageal junction include hiatal hernia. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/gastroesopha...eport.html .
MACK: 13.07 (+0.41), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22), AZN: 68.74 (-0.55), BMY: 68.00 (+0.36), EXEL: 3.34 (-0.03)
Esophageal Cancer Therapeutics Pipeline Review 2015 - 40 Companies & 57 Drug Profiles
M2 - Wed Mar 11, 7:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2mqnm8/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Advaxis, Inc. - Amgen Inc. - ArQule, Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellectar Biosciences, Inc. - Cerulean Pharma, Inc. - Daiichi Sankyo Company, Limited - Genmab A/S - GlaxoSmithKline plc - Glycotope GmbH - Hutchison MediPharma Limited - ImmunoFrontier, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Karyopharm Therapeutics, Inc. - Mebiopharm Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Omeros Corporation - Omnitura Therapeutics Inc. - Oncolys BioPharma Inc. - Ono Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2m...eal_cancer
CLRB: 2.80 (+0.06), IMMU: 4.22 (+0.10), ADXS: 20.90 (+0.82), CERU: 6.37 (+0.22), IMGN: 8.67 (+0.08), ARQL: 1.85 (-0.02), AMGN: 163.44 (+1.08), GSK: 44.66 (-0.11), BMY: 68.00 (+0.36), OMER: 20.99 (+0.11), MACK: 13.07 (+0.41), BLCM: 22.18 (-0.84), AZN: 68.74 (-0.55), AVEO: 1.24 (+0.05), NVS: 104.06 (+0.31), KPTI: 27.02 (+2.21), CELGZ: 2.60 (unch)
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
OCAT: 6.42 (+0.21), ITEK: 5.85 (+0.05), NBS: 2.37 (-0.01), FOMX: 11.36 (-0.05), AERI: 11.22 (-0.04), OCUL: 26.43 (+0.16), AGN: 240.22 (+2.88), CANF: 2.43 (+0.10), ACAD: 40.31 (+1.14), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22), TEVA: 60.19 (-0.04), OHRP: 2.77 (+0.04), CBMG: 29.54 (+2.04)
Gilead/Ono Pharmaceutical Ink Deal for Blood Cancer Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 3:12PM CST
Gilead Sciences, Inc. and Ono Pharmaceutical Co., Ltd. announced that they have entered into an agreement for ONO-4059.
VRX: 225.43 (+0.80), GILD: 111.00 (+1.70), SCMP: 16.04 (+0.10)
Gilead teams up with Ono to develop cancer med
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 10:19AM CST
GILD: 111.00 (+1.70)
ONO and Gilead Announce Exclusive License Agreement to Develop BTK Inhibitor, ONO-4059, for the Treatment of B-cell Malignancies and Other Diseases
Business Wire - Fri Dec 19, 12:00AM CST
ONO PHARMACEUTICAL CO., LTD. ("ONO"
and Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the companies have entered into an exclusive license agreement for the development and commercialization of ONO-4059, ONO's oral Bruton's tyrosine kinase (BTK) inhibitor for the treatment of B-cell malignancies and other diseases. Under the terms of the agreement, Gilead will pay ONO an upfront payment plus additional payments based upon achievement of certain development, regulatory and commercial milestones. The companies will collaborate jointly on global development of ONO-4059. Gilead will have exclusive rights to develop and commercialize ONO-4059 in all countries of the world outside of Japan, South Korea, Taiwan, China and the Association of Southeast Asian Nations (ASEAN) countries, where ONO retains development and commercialization rights. GILD: 111.00 (+1.70)
Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.71 (unch), PFE: 33.98 (-0.01), INCY: 107.65 (+0.79), CLDX: 26.26 (+0.45), AMGN: 163.44 (+1.08), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), MNTA: 20.22 (-0.07), PVCT: 0.85 (-0.02), VICL: 0.92 (-0.01), AZN: 68.74 (-0.55), DCTH: 0.86 (+0.03), NVS: 104.06 (+0.31), CELGZ: 2.60 (unch)
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/kspvsg/recurrent_head) has announced the addition of the "Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Genentech, Inc. - MedImmune, LLC - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Merck KGaA - Oncolytics Biotech Inc. - Panacea Biotec Limited - PCI Biotech AS - Glycotope GmbH - VentiRx Pharmaceuticals, Inc. - Immunovative Therapies, Ltd. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/ks...rrent_head
ONCY: 0.71 (unch), PFE: 33.98 (-0.01), AMGN: 163.44 (+1.08), NVS: 104.06 (+0.31)
Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors
Business Wire - Wed Dec 10, 5:00AM CST
Ono Pharmaceutical Co.,Ltd. (Tokyo: 4528), Bristol-Myers Squibb Company (NYSE:BMY) and Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151,"Kyowa Hakko Kirin"
announced today the companies have entered into a clinical trial collaboration agreement to conduct a Phase 1 combination study with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, and mogamulizumab, an anti-CCR4 antibody. The study, which will be conducted in Japan, will focus on evaluating the safety, tolerability and anti-tumor activity of combining Opdivo and mogamulizumab as a potential treatment option for patients with advanced or metastatic solid tumors. BMY: 68.00 (+0.36)
Global Irritable Bowel Syndrome Therapeutics Pipeline Review 2014 - 28 Companies & 33 DRug Profiles
M2 - Fri Nov 07, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/scknzx/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Astellas Pharma Inc. - Ono Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - AlbireoPharma - Lexicon Pharmaceuticals, Inc. - Yuhan Corporation - Alba Therapeutics Corporation - Ironwood Pharmaceuticals, Inc. - Rottapharm SpA - Tioga Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Drais Pharmaceuticals, Inc. - Synergy Pharmaceuticals, Inc. - Protagonist Therapeutics Inc. - Alfa Wassermann S.p.A - RaQualia Pharma Inc. - Furiex Pharmaceuticals, Inc. - Hanmi Pharmaceuticals, Co. Ltd. - X-BODY BioSciences, Inc. - ImmusanT, Inc. - AltheRx Pharmaceuticals, Inc. - GIcare Pharma Inc - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/sc...able_bowel
SGYP: 3.90 (+0.38), SYN: 1.94 (+0.07), IRWD: 14.30 (+0.02), LXRX: 1.01 (unch), AZN: 68.74 (-0.55), TEVA: 60.19 (-0.04)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 33.98 (-0.01), INCY: 107.65 (+0.79), ONTX: 2.81 (+0.09), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), STML: 13.42 (-0.01), SNTA: 2.34 (+0.01), KBIO: 0.50 (unch), BPTH: 1.30 (+0.06), CELGZ: 2.60 (unch), NVS: 104.06 (+0.31)
Global B-Cell Non-Hodgkin Lymphoma Therapeutics Pipeline Review H2 2014 - 43 Drug Profiles from 28 Leading Pharma Companies
M2 - Thu Oct 23, 10:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72dlvw/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - Sanofi - Seattle Genetics, Inc. - Genentech, Inc. - MedImmune, LLC - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Biocon Limited - Ono Pharmaceutical Co., Ltd. - Sandoz Inc. - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics, Inc. - Portola Pharmaceuticals, Inc. - Pharmacyclics, Inc. - Takara Bio Inc. - Simcere Pharmaceutical Group - Spectrum Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - LFB S.A. - Eagle Pharmaceuticals Inc. - Areta International s.r.l. - Molecular Templates Inc. - Aprogen, Inc. - BioMedics Japan Inc. For more information visit http://www.researchandmarkets.com/research/72dlvw/bcell
IMMU: 4.22 (+0.10), PTLA: 37.66 (+0.45), PCYC: 258.23 (+2.81), INCY: 107.65 (+0.79), AMGN: 163.44 (+1.08), SPPI: 6.56 (-0.12), BMY: 68.00 (+0.36), EGRX: 61.94 (+1.02), SGEN: 40.50 (+0.56), MRK: 60.01 (-0.22), CELGZ: 2.60 (unch)
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - 22 Drug Profiles from 11 Companies
M2 - Fri Sep 12, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c97xhn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Santen Pharmaceutical Co., Ltd. - Oxford BioMedica plc - Sylentis S.A. - Ono Pharmaceutical Co., Ltd. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Amakem NV Drug Profiles - tafluprost - (tafluprost timolol maleate) - latanoprostene bunod - latanoprost - OPC-1085EL - trabodenoson - SYL-040012 - RO-5093151 - latanoprost - AR-13324 - AMA-0076 - ONO-9054 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - latanoprost SR - Glaucoma-GT - ATS-8535 - Small Molecule for Glaucoma For more information visit http://www.researchandmarkets.com/research/c97xhn/openangle
AERI: 11.22 (-0.04)
Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer
MGNX: 32.83 (+1.99), ADXS: 20.90 (+0.82), IMMU: 4.22 (+0.10), CERU: 6.37 (+0.22), AMGN: 163.44 (+1.08), BMY: 68.00 (+0.36), CTIC: 1.78 (-0.02), GSK: 44.66 (-0.11), OMER: 20.99 (+0.11), MACK: 13.07 (+0.41), SNTA: 2.34 (+0.01), GILD: 111.00 (+1.70), KITE: 46.39 (-3.63), NVS: 104.06 (+0.31)
Merck KGaA-Ono Pharma Deal Ends - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 5:15PM CDT
Merck KGaA (MKGAF) has decided to terminate its license agreement with Ono Pharma related to the development of Ono Pharma's multiple sclerosis candidate, ceralifimod (ONO-4641).
GILD: 111.00 (+1.70), ARIA: 9.12 (+0.23)
Ocular Hypertension - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bzfhkc/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Allergan, Inc. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. - Kowa Company, Ltd. - Ono Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Can-Fite BioPharma Ltd. - Lexicon Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - D. Western Therapeutics Institute, Inc. - Icon Bioscience, Inc. - Otsuka Holdings Co., Ltd. - Ocular Therapeutix, Inc. - Amakem NV - High Point Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/bzfhkc/ocular
CANF: 2.43 (+0.10), AGN: 240.22 (+2.88), LXRX: 1.01 (unch), AERI: 11.22 (-0.04)
